| Literature DB >> 28640591 |
Jeffrey J Sutherland1, Ryan D Morrison1, J Scott Daniels1, Stephen B Milne1, Timothy P Ryan1.
Abstract
There are multiple treatment options for depression, anxiety, psychosis, and other psychiatric disorders, and psychiatry patients are often comorbid with complex, polypharmacy treatment regimens. Unlike cardiovascular disease and diabetes, there are no readily available biomarkers to gauge treatment success with psychotropic medications, often resulting in subjective determination of medication therapy effectiveness. The physiochemical properties of psychiatric medications in general lend themselves to quantitative measurement in blood, offering an avenue to optimize treatment for each patient. Herein, we describe a novel application that employs comprehensive therapeutic drug monitoring of both psychiatric and nonpsychiatric medications to holistically personalize therapy for complex psychiatry patients.Entities:
Keywords: Adherence; DDI; compliance; drug Interactions; medical record reconciliation; medication therapy management; pharmacogenetics; precision medicine; therapeutic drug monitoring
Mesh:
Substances:
Year: 2017 PMID: 28640591 DOI: 10.1021/acschemneuro.7b00209
Source DB: PubMed Journal: ACS Chem Neurosci ISSN: 1948-7193 Impact factor: 4.418